27 Participants Needed

TENS for Chemotherapy-Induced Neuropathy in Breast Cancer

Recruiting at 2 trial locations
MB
Overseen ByManali Bhave, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Emory University
Must be taking: Paclitaxel, Docetaxel
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves patients actively undergoing chemotherapy, it seems likely that you can continue your current treatment.

Is TENS safe for use in humans?

TENS (Transcutaneous Electrical Nerve Stimulation) is generally considered safe for use in humans, including those with cancer, as it involves using a mild electrical current to stimulate nerves and can be self-administered to relieve pain.12345

How does the TENS treatment differ from other treatments for chemotherapy-induced neuropathy?

TENS (Transcutaneous Electrical Nerve Stimulation) is unique because it uses mild electrical currents to stimulate nerves through electrodes placed on the skin, which can be self-administered at home. Unlike other treatments that may involve medications, TENS offers a non-drug approach to managing pain and symptoms associated with chemotherapy-induced neuropathy.14567

What is the purpose of this trial?

This phase II trial examines transcutaneous electrical nerve stimulation (TENS) in patients with stage I-III breast cancer with chemotherapy induced peripheral neuropathy. TENS is a procedure in which mild electric currents are applied to some areas of the skin to potentially improve neuropathy. This trial may help determine if TENS is feasible and effective for the treatment of peripheral neuropathy symptoms while on chemotherapy.

Research Team

Manali Bhave, MD | Winship Cancer ...

Manali A Bhave, MD

Principal Investigator

Emory University Hospital/Winship Cancer Institute

Eligibility Criteria

This trial is for women with stage I-III breast cancer experiencing nerve pain due to chemotherapy. They must be undergoing treatment with paclitaxel or docetaxel, not pregnant, able to follow the study plan, and use birth control if of childbearing age. Excluded are those with skin issues where TENS pads go, epilepsy, electronic implants like pacemakers, existing neuropathy or prior neurotoxic chemo.

Inclusion Criteria

I am mentally and physically able to follow the study's requirements.
I agree to use birth control or practice abstinence during the study.
I am currently receiving chemotherapy with paclitaxel or docetaxel for stage I-III breast cancer.
See 7 more

Exclusion Criteria

I have a history of epilepsy.
I have skin issues where the TENS pads would go.
Pregnancy
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo TENS therapy at home daily over 1 hour for 14 days

2 weeks
Daily home sessions

Follow-up

Participants are monitored for changes in symptoms and functional impairment, with assessments at 2 and 6 weeks

4 weeks
Assessments at 2 and 6 weeks

Treatment Details

Interventions

  • Transcutaneous Electrical Nerve Stimulation
Trial Overview The trial tests Transcutaneous Electrical Nerve Stimulation (TENS) on patients with early-stage breast cancer who have nerve pain from chemotherapy. It involves mild electric currents applied to the skin over two weeks to see if it eases their symptoms.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Supportive Care (TENS)Experimental Treatment1 Intervention
Patients undergo TENS therapy daily over 1 hour for 14 days in the absence of disease progression or unacceptable toxicity.

Transcutaneous Electrical Nerve Stimulation is already approved in United States, European Union, Canada for the following indications:

πŸ‡ΊπŸ‡Έ
Approved in United States as TENS for:
  • Pain management
  • Musculoskeletal pain
  • Neck pain
  • Back pain
  • Knee osteoarthritis pain
  • Overactive bladder
  • Urinary retention
  • Temporomandibular joint dysfunction
  • Essential tremor
πŸ‡ͺπŸ‡Ί
Approved in European Union as TENS for:
  • Pain management
  • Musculoskeletal pain
  • Neck pain
  • Back pain
  • Knee osteoarthritis pain
  • Overactive bladder
  • Urinary retention
  • Temporomandibular joint dysfunction
  • Essential tremor
πŸ‡¨πŸ‡¦
Approved in Canada as TENS for:
  • Pain management
  • Musculoskeletal pain
  • Neck pain
  • Back pain
  • Knee osteoarthritis pain
  • Overactive bladder
  • Urinary retention
  • Temporomandibular joint dysfunction
  • Essential tremor

Find a Clinic Near You

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials
1,735
Recruited
2,605,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Findings from Research

A single-arm study involving 29 patients demonstrated that transcutaneous electrical nerve stimulation (TENS) is feasible and acceptable for treating chemotherapy-induced peripheral neuropathy (CIPN), with 85% of participants completing the 6-week study.
Participants experienced significant improvements in various symptoms of CIPN, including a 52% reduction in pain and a 30% reduction in tingling, suggesting that TENS could be an effective home-based treatment option for managing CIPN after chemotherapy.
Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.Gewandter, JS., Chaudari, J., Ibegbu, C., et al.[2021]
In a pilot study involving 20 patients with cancer pain, transcutaneous electrical nerve stimulation (TENS) was found to be safe, with 85% of patients using intensity-modulated TENS (IMT) reporting at least slight pain improvement compared to 50% with placebo TENS (PBT).
However, the overall change in average pain intensity did not significantly differ between IMT and PBT, suggesting that while TENS may be desired by patients, it may not provide greater analgesic effects than placebo.
Transcutaneous electrical nerve stimulation for advanced cancer pain inpatients in specialist palliative care-a blinded, randomized, sham-controlled pilot cross-over trial.Siemens, W., Boehlke, C., Bennett, MI., et al.[2021]
A randomized clinical trial involving 142 participants evaluated the efficacy of a wearable, app-controlled TENS device for treating chemotherapy-induced peripheral neuropathy (CIPN), showing promising results for pain and cramping symptoms, although the primary outcome did not reach statistical significance.
The study demonstrated that conducting a trial of TENS for CIPN is feasible within the National Cancer Institute Community Oncology Research Program, indicating a strong basis for future confirmatory trials.
Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial.Gewandter, JS., Culakova, E., Davis, JN., et al.[2023]

References

Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. [2021]
Transcutaneous electrical nerve stimulation for advanced cancer pain inpatients in specialist palliative care-a blinded, randomized, sham-controlled pilot cross-over trial. [2021]
Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial. [2023]
Effects of transcutaneous electrical nerve stimulation on chemotherapy-induced peripheral neuropathy symptoms (CIPN): a preliminary case-control study. [2020]
Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Systematic Review. [2022]
TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients. [2023]
Phase 2 Study of Acupuncture-Like Transcutaneous Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security